On June 17, 2022, AbbVie announced that the FDA expanded approval for Skyrizi® (risankizumab-rzaa) for the treatment of moderate to severe active Crohn’s disease in adult patients. Crohn’s disease is a type of inflammatory bowel disease (IBD) characterized by inflammation in the digestive tract. Patients with Crohn’s disease often experience abdominal pain, severe diarrhea and weight loss. There is no known cure for Crohn’s disease, but patients may enter a symptom-free period, known as clinical remission, with proper treatment. Skyrizi® was originally approved for moderate to severe plaque psoriasis in 2019. Its approval was expanded to include the treatment of active psoriatic arthritis in January 2022. The safety and efficacy of Skyrizi® in the treatment of Crohn’s disease was evaluated in two randomized, double-blind, placebo-controlled induction (initiation of treatment) clinical trials, ADVANCE and MOTIVATE, and a maintenance clinical trial, FORTIFY. All three trials demonstrated significant achievement of either clinical remission of symptoms or an endoscopy confirmed disease state improvement of greater than 50% from baseline. Common side effects include headache, joint pain and injection site relations. The recommended starting dose for Skyrizi® when treating Crohn’s disease is a 600 mg intravenous infusion given monthly for three months, after which patients self-administer a 360 mg injection under the skin every eight weeks for maintenance treatment. Skyrizi® is the first drug in its class approved for Crohn’s disease. This approval provides gastroenterologists with an additional treatment option for adult patients with moderate to severely active Crohn’s disease.